Vericel Co. (NASDAQ:VCEL) Receives $51.83 Average Target Price from Brokerages


Share on StockTwits

Shares of Vericel Co. (NASDAQ:VCEL) have received a consensus rating of “Buy” from the ten ratings firms that are presently covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $51.83.

Several brokerages have issued reports on VCEL. Stephens began coverage on shares of Vericel in a research note on Thursday, December 17th. They set an “overweight” rating and a $31.00 target price on the stock. Oppenheimer downgraded shares of Vericel from an “outperform” rating to a “market perform” rating in a research note on Monday, January 11th. LADENBURG THALM/SH SH boosted their price target on shares of Vericel from $27.50 to $44.00 and gave the company a “buy” rating in a report on Tuesday, January 19th. BTIG Research upped their price objective on shares of Vericel from $45.00 to $56.00 in a report on Monday, February 22nd. Finally, Zacks Investment Research cut shares of Vericel from a “buy” rating to a “hold” rating in a report on Saturday, February 27th.

NASDAQ VCEL opened at $55.47 on Monday. The stock has a market capitalization of $2.56 billion, a P/E ratio of -5,547,000.00 and a beta of 3.11. Vericel has a 1 year low of $9.36 and a 1 year high of $60.00. The business’s fifty day moving average is $49.80 and its two-hundred day moving average is $33.97.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings results on Tuesday, February 23rd. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.05. Vericel had a return on equity of 0.13% and a net margin of 0.12%. The company had revenue of $45.23 million for the quarter, compared to analysts’ expectations of $45.05 million.

In other Vericel news, insider Jonathan Mark Hopper sold 17,924 shares of the business’s stock in a transaction on Tuesday, March 30th. The shares were sold at an average price of $51.40, for a total transaction of $921,293.60. Following the completion of the transaction, the insider now owns 27,966 shares of the company’s stock, valued at approximately $1,437,452.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Dominick Colangelo sold 40,000 shares of the business’s stock in a transaction on Monday, March 29th. The stock was sold at an average price of $51.01, for a total transaction of $2,040,400.00. Following the transaction, the chief executive officer now directly owns 206,540 shares of the company’s stock, valued at approximately $10,535,605.40. The disclosure for this sale can be found here. 4.30% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Everence Capital Management Inc. acquired a new position in shares of Vericel during the first quarter valued at about $360,000. Rollins Financial acquired a new position in shares of Vericel during the fourth quarter valued at about $154,000. Dimensional Fund Advisors LP raised its position in shares of Vericel by 9.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 506,214 shares of the biotechnology company’s stock valued at $15,633,000 after buying an additional 44,061 shares during the last quarter. Norges Bank acquired a new position in shares of Vericel during the fourth quarter valued at about $508,000. Finally, Virtu Financial LLC acquired a new position in shares of Vericel during the fourth quarter valued at about $245,000. 93.11% of the stock is owned by institutional investors and hedge funds.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.

Featured Article: What is the Ex-Dividend Date in Investing?

Analyst Recommendations for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.